AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...

Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU (a HER2 directed ADC) in March 2019, and DS-1062 (a TROP2 directed ADC) in July 2020 ...

AstraZeneca and Daiichi Sankyo are evaluating Datroway alone and with Tagrisso (osimertinib) in other advanced or metastatic EGFR-mutated NSCLC settings in the TROPION-Lung14 and TROPION-Lung15 ...

AstraZeneca and Daiichi Sankyo's Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S. Provided by Dow Jones Jun 23, 2025, 11:33:00 PM ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...

Daiichi Sankyo has been particularly active in this field, and the company’s collaborations including the one with AstraZeneca, have led to the development of successful drugs like Enhertu ...

Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast cancer drug Dato-DXd. Read more here.

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

Overview DSKYF Daiichi Sankyo Co Ltd $25.10 6.81 % DSNKY Daiichi Sankyo Co Ltd $24.21 -1.57 % On Monday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca plc and Daiichi Sankyo’s ...